Alzheimer's & Dementia·13 AugLong-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension studyTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecMeaningful Clinical Impact of ABvac40 in Early‐Stage Alzheimer’s Disease: Results from the AB1601 Phase 2 StudyTrial in peopleInterventionsPaper